News & Press Releases

PneumRx, a BTG International group company, is focused on developing minimally invasive solutions for unmet medical needs in pulmonary medicine. Please click on a link below to learn more about PneumRx and PneumRx Coils, or to find us at our next conference or event.


PneumRx® Coils included in new global clinical guidelines and given positive recommendation to treat severe emphysema patients in France

December 05, 2016

London, UK, 5 December 2016: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the inclusion of treatment with lung coils in guidelines for the management of chronic obstructive pulmonary disease (COPD) published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD). At the same time, the French Ministry of Health has published its positive recommendations regarding PneumRx® Coils on its website.

Read More

PneumRx® Coils: Neue randomisierte klinische Studien bestätigen wiederholt positive Ergebnisse bei Patienten mit fortgeschrittenem Lungenemphysem

March 17, 2016

Für die Behandlung des fortgeschrittenen Lungen-emphysems mit dem endobronchialen Coil-System existiert eine umfassende Datenlage: Nach der kürzlich publizierten REVOLENS-Studie steht mit RENEW die dritte Phase-III-Studie zur Behandlung des fortgeschrittenen Lungenemphysems mit Coils unmittelbar vor der Veröffentlichung. Wie bei allen anderen randomisierten kontrollierten Studien (RCTs) wurde auch in der RENEW-Studie der primäre Endpunkt erreicht. Insgesamt wurden bereits mehr als 1.100 Patienten in Studien untersucht: 461 in randomisierten kontrollierten Studien, mehr als 650 im laufenden Register.1-4 Auf dem diesjährigen Kongress der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin (DGP) in Leipzig diskutierten Experten die Bedeutung der Studienergebnisse für die klinische Praxis.

Read more

Dr. Joseph Cicenia from the Cleveland Clinic, comments on the recent REVOLENS publication in the Journal of American Medical Association. (JAMA)

February 09, 2016

Dr. Joseph Cicenia from the Cleveland Clinic, comments on the recent REVOLENS publication in the Journal of American Medical Association.

Read more

REVOLENS Randomized Clinical Trial

January 12, 2016

Professors Gaetan Deslee and Charles-Hugo Marquette, Primary Investigators of the REVOLENS Study Group, “Lung Volume Reduction Coil Treatment vs. Usual Care in Patients with Severe Emphysema: The REVOLENS Randomized Clinical Trial” is published in the JAMA 2016;315(2):175-184.Doi:10.1001/jama.2015.17821.

More Information

BTG Announces Positive Data from RENEW study of PneumRx® Coils

December 14, 2015

Study meets all primary and secondary endpoints London, UK, 14 December : BTG plc (LSE: BTG), the specialist healthcare company, today announces the successful outcome of the RENEW study, the pivotal US randomised controlled clinical trial comparing the safety and efficacy of the PneumRx endobronchial coil implant (EBCI) with a medical therapy control group in patients with homogeneous and/or heterogeneous severe emphysema.

Read Press Release

COPD: Was kann Linderung verschaffen?

April 23, 2015

Es ist eine der häufigsten Todesursachen überhaupt - häufiger noch als Herzinfarkt, aber kaum jemand kennt ihren Namen: COPD, die chronisch obstruktive Bronchitis. Zur häufigsten Ursache dieser Erkrankung zählt langjähriges Zigarettenrauchen.

Read article

PneumRx Acquired by BTG for up to $475 Million

December 04, 2014

PneumRx, Inc. (, a leader in the field of interventional pulmonology, today announced that it has signed an agreement to be acquired by BTG Plc (LSE:BTG) in a deal worth up to $475 million, based on an initial consideration of $230 million and up to $245 million in performance-related milestone payments. Based in London, BTG is an international specialist healthcare company that is active in interventional medicine and specialty pharmaceuticals. Their current interventional portfolio includes site-specific treatments for severe blood clots including pulmonary embolisms, liver tumors, and varicose veins. These therapies are differentiated, minimally invasive, and marketed to specialist physician groups.

Read Press Release

PneumRx Completes RENEW Pivotal Trial Enrollment – Study Results Will be Used to Support PMA Application for the RePneu Coil System

October 22, 2014

PneumRx, Inc. (, a leader in the field of interventional pulmonology, today announced completion of enrollment in their RENEW Study, nearly 3 months ahead of schedule. The RENEW Clinical Study is the FDA-approved IDE pivotal trial for the PneumRx RePneu Coil System, a treatment for severe emphysema.

Read Press Release

Leading Pulmonologists Draw National Media Focus to Endobronchial Coil Treatment for Severe Emphysema

May 19, 2014

A revolutionary new treatment for severe emphysema, which could potentially help millions of patients suffering from a debilitating disease, has been featured recently on national media channels across the US. Leading pulmonologists and premier medical centers have been reaching out to media outlets to share their enthusiasm about RePneu endobronchial coil therapy – a new treatment for emphysema patients. The stories have highlighted physicians and patients taking part in an FDA-approved clinical study to evaluate endobronchial nitinol coil implants in patients with severe emphysema. NBC News, CBS News and Fox News all have run prime-time segments in Los Angeles, Houston, Raleigh and New York. RePneu Coil treatment was also recently featured on the front page of the Wall Street Journal’s Health section. Local networks across the country, from North Dakota to Florida, have picked up and re-broadcast the segments, generating a flood of calls to treating centers from patients interested in participating in the RENEW Study.

Read Press Release

40 Minute Wonder Op Gets Damaged Lungs Working Again

May 12, 2014

Thousands of Britons have breathing difficulties due to emphysema, but a new procedure could help them.

Read Article